

CANADIAN CANCER TRIALS GROUP

RADIATION ONCOLOGY QUALITY ASSURANCE COMMITTEE

AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: CARLYLE

DATE: APRIL 28, 2017

TIME: 1:00 PM – 4:00 PM

CHAIR: A. NICHOL

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand the priorities and goals of the CCTG Radiation Oncology Quality Assurance Committee.
- To become familiar with international efforts regarding radiation oncology quality assurance within the context of clinical trials.
- To describe Canadian led initiatives for quality radiotherapy.
- To become familiar with radiation oncology quality assurance needs and challenges in the conduct of clinical studies.
- To identify areas for research and publication within clinical trials conducted by CCTG and its collaborative partners

| | | |
|---------------------------------|--|-------------------------|
| 1:00 pm | Welcome | A. Nichol |
| Update of ongoing trials | | |
| 1:05 pm | SBRT vs. conventional palliative radiotherapy for spinal metastases. SC.24 | A. Sahgal/ Y. Lee |
| 1:20 pm | Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in BRAF Mutation–Positive Malignant Melanoma and brain metastases. IND.224 | A. Sahgal/ Y. Lee |
| 1:35 pm | Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. PR.19 | G. Morton/ E. Vigneault |
| 1:45 pm | Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. HE.1 | A. Fairchild/ L. Dawson |

Continued on next page...

CANADIAN CANCER TRIALS GROUP

RADIATION ONCOLOGY QUALITY ASSURANCE COMMITTEE

AGENDA

Protocols in development

- | | | |
|----------------|---|--|
| 2:00 pm | TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer MA.39 | T. Whelan |
| 2:15 pm | Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Maintenance Durvalumab vs Durvalumab plus RT followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC). HN.9 | K. Sultanem |
| 2:30 pm | EVADER: Phase II trial of Elective Volume Adjusted De-Escalation RT in Patients with low-risk HPV-related oropharyngeal squamous cell ca HN.10 | S. Bratman |
| 2:45 pm | A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases CE.7 | D. Roberge |
| 3:00 pm | Activities of the ROQAC <ul style="list-style-type: none">• Clinical Trials proposed at the Radiation Oncology Forum• Analysis Historical RTQA review | M. McKenzie A. Fairchild/ A. Nichol |
| 3:50 pm | Other business | A. Nichol |
| 4:00 pm | Meeting Adjourned | |